Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Practice Guideline
. 2021 Oct;110(4):888-896.
doi: 10.1002/cpt.2149. Epub 2021 Feb 9.

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy

Kristine R Crews  1 , Andrew A Monte  2 , Rachel Huddart  3 , Kelly E Caudle  1 , Evan D Kharasch  4 , Andrea Gaedigk  5   6 , Henry M Dunnenberger  7 , J Steven Leeder  5   6 , John T Callaghan  8 , Caroline Flora Samer  9 , Teri E Klein  3 , Cyrine E Haidar  1 , Sara L Van Driest  10 , Gualberto Ruano  11 , Katrin Sangkuhl  3 , Larisa H Cavallari  12 , Daniel J Müller  13 , Cynthia A Prows  14 , Mohamed Nagy  15 , Andrew A Somogyi  16 , Todd C Skaar  8
Affiliations
Practice Guideline

Clinical Pharmacogenetics Implementation Consortium Guideline for CYP2D6, OPRM1, and COMT Genotypes and Select Opioid Therapy

Kristine R Crews et al. Clin Pharmacol Ther. 2021 Oct.

Abstract

Opioids are mainly used to treat both acute and chronic pain. Several opioids are metabolized to some extent by CYP2D6 (codeine, tramadol, hydrocodone, oxycodone, and methadone). Polymorphisms in CYP2D6 have been studied for an association with the clinical effect and safety of these drugs. Other genes that have been studied for their association with opioid clinical effect or adverse events include OPRM1 (mu receptor) and COMT (catechol-O-methyltransferase). This guideline updates and expands the 2014 Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline for CYP2D6 genotype and codeine therapy and includes a summation of the evidence describing the impact of CYP2D6, OPRM1, and COMT on opioid analgesia and adverse events. We provide therapeutic recommendations for the use of CYP2D6 genotype results for prescribing codeine and tramadol and describe the limited and/or weak data for CYP2D6 and hydrocodone, oxycodone, and methadone, and for OPRM1 and COMT for clinical use.

PubMed Disclaimer

References

    1. Crews KR et al.Clinical Pharmacogenetics Implementation Consortium guidelines for cytochrome P450 2D6 genotype and codeine therapy: 2014 update. Clin Pharmacol Ther 95, 376–82 (2014). - PMC - PubMed
    1. PharmGKB. Gene Reference Materials for CYP2D6. <https://www.pharmgkb.org/page/cyp2d6RefMaterials>. AccessedDecember 1 2020.
    1. CPIC. CPIC Guideline for Opioids based on genotype. <https://cpicpgx.org/guidelines/guideline-for-codeine-and-cyp2d6/>.
    1. Gaedigk A, Simon SD, Pearce RE, Bradford LD, Kennedy MJ & Leeder JS The CYP2D6 activity score: translating genotype information into a qualitative measure of phenotype. Clin Pharmacol Ther 83, 234–42 (2008). - PubMed
    1. Caudle KE et al.Standardizing CYP2D6 Genotype to Phenotype Translation: Consensus Recommendations from the Clinical Pharmacogenetics Implementation Consortium and Dutch Pharmacogenetics Working Group. Clin Transl Sci 13, 116–24 (2020). - PMC - PubMed

Publication types